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Abstract
Background: Mood disorders in pregnancy and post-partum period are common and considered as a public
health issue. Researchers have studied the relationship between low serum vitamin D concentration and perinatal
depression, although no clinical trial has been conducted on vitamin D’s effects on depression related to childbirth.
This study evaluated the effect of vitamin D3 supplementation on perinatal depression scores.
Methods: This randomized clinical trial was done in pregnant women who were under prenatal care in a teaching
hospital in Shiraz, Iran. The inclusion criteria were: being 18 years or older, no history of mental illness and internal
diseases, a singleton live fetus, without any pregnancy complications, gestational age of 26–28 weeks upon
enrollment, and depression score of 0 to 13. The Edinburgh Postnatal Depression scale was used to evaluate
depression scores. A total of 169 participants were assigned to the two groups of placebo and vitamin D through
block randomization design. Vitamin D group received 2000 IU vitamin D3 daily from 26 to 28 weeks of gestation
until childbirth. Maternal serum 25-hydroxyvitamin D concentrations were measured at baseline and childbirth.
Besides, depression scores were evaluated four times: at 26–28 and 38–40 weeks of gestation, and finally at
4 and 8 weeks after birth.
Results: The two groups were similar in relation to baseline 25-hydroxyvitamin D concentrations. However, at
childbirth, the vitamin D group had significantly higher 25-hydroxyvitamin D concentration in comparison to the
control group (p < 0.001). At baseline, no correlation was observed between 25-hydroxyvitamin D concentration
and depression score (r = 0.13, p = 0.09). There was no significant difference between the two study groups in
relation to the baseline depression score. While, the vitamin D group had greater reduction in depression scores
than the control group at 38–40 weeks of gestation (p = 0.01) also, at 4 and 8 weeks after birth (p < 0.001).
Conclusions: The present trial showed that consuming 2000 IU vitamin D3 daily during late pregnancy was
effective in decreasing perinatal depression levels. We suggest further clinical trial in pregnant mothers who
are at risk for postnatal depression.
Trial registration: Iranian Registry of Clinical Trials IRCT2015020310327N11. Date of registration: March 9th 2015.
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Background
Mood disorders in pregnancy and post-partum period are
common and considered as a public health issue. In recent
decades researchers have paid great amount of attention
to these subjects and showed that mood illness related to
childbirth can lead to serious complications for mother,
fetus, newborn and family [1, 2]. Evidence shows that
postnatal depression is an extension of antenatal depres-
sion which continues postpartum. This problem can have
negative effects on infant development and can cause
behavioral, cognitive, social and emotional problems
in infant which could continue throughout childhood
[3–5].
Prevalence of postpartum depression varies throughout
the world; however researchers have used different scales
and cut off points to describe this psychological disorder.
In a systematic review by Halbreich and Karkun, the stud-
ies from 40 different countries were reviewed. This study
has reported the prevalence of postnatal depression up to
60 % [6]. The prevalence of postnatal depression in some
Asian countries has been reported between 22 and 46.9 %
[7, 8]. Several studies have shown a high prevalence
of postnatal depression in Iran. In the meta-analysis of
Veisani et al., postnatal depression was reported at 25.3 %
[9], and in two recent studies in eastern and central part
of Iran, the prevalence has been reported at 28.9–34.8 %
[10, 11].
The spread and importance of postpartum depression
have led researchers to create preventative methods such
as educational programs, modified care, dietary supple-
ments, antidepressant medication and social support
[12–14].
In human body, the most important source of vitamin D
is the skin where 7-dehydrocholesterol is converted to
vitamin D3 in response to UV exposure. Both cutaneous
production and dietary consumption of vitamin D must
undergo two hydroxylations in the body for activation.
Following the first hydroxylation in the liver, 25-hydroxyvi-
tamin D is produced. However, 25-hydroxyvitamin D re-
quires an additional hydroxylation in the kidneys to form
the biologically active form of vitamin D, 1, 25(OH) 2D.
Serum 25-hydroxyvitamin D as the main precursor of 1,
25(OH) 2D has a circulating half-life of 2–3 weeks. While,
the circulating half-life of 1, 25(OH) 2D is around 4 h. Its
blood concentration is 1000 times less than 25-hydroxyvita-
min D. Serum levels of PTH, calcium, and phosphate have
influence on regulatory and production of 1,25(OH)2D.
Serum levels of 25-hydroxyvitamin D reflects the body’s
vitamin D reserves and this is a well-known indicator for
examining vitamin D status [15]. Several studies have
revealed that vitamin D supplementation can raise vitamin
D reserves gradually, according to baseline concentration of
vitamin D, dose and duration of consumption [16–18].
In accordance to a guideline by Holick et al., 6–8 weeks
consumption of a high dose vitamin D supplement are
essential to obtain an adequate blood reserves of vitamin
D [19].
It seems that in addition to calcium homeostasis and
bone health, vitamin D is also essential for brain develop-
ment and function [20, 21]. The special nuclear receptors
for 1, 25-dihydroxyvitamin D and also essential enzymes
for hydroxylation of vitamin D are found in the central
nervous system. Therefore, the brain can regionally acti-
vate vitamin D, which implicates vitamin D’s role in brain
function more prominent [22–25].
Studies have shown that low serum 25-hydroxyvitamin D
concentration is associated with psychological symptoms
like anxiety, depression and reduced cognitive function
[26, 27]. Few case reports have suggested an interaction
between season or latitude and psychological problems
[28, 29]. In a study by Mozaffari- Khosravi et al., high
doses of vitamin D have been effective in men and women
who were depressed [30]. Li et al. suggested that more
accurate clinical trials are required to reach a conclusion
about the effectiveness of vitamin D on depression [31].
Considering the possible connection between low serum
vitamin D and depression, researchers studied the relation-
ship between low vitamin D and perinatal depression.
Murphy et al. in a study with a small sample size (97 partici-
pants), observed an association between maternal low
serum concentrations of 25-hydroxyvitamin D and high de-
pression scores within several post-partum visits [32]. Rob-
inson et al. studied the relationship between the maternal
serum 25-hydroxyvitamin D concentrations measured in
the 18th week of gestation and postnatal depression in 796
people. They found that low serum 25-hydroxyvitamin D
levels in the second trimester were a risk factor for postna-
tal depression. Depression scores were measured three days
after childbirth using a questionnaire based on the Edin-
burgh Postnatal Depression scale (EPDS) [33]. Brandenburg
et al. studied the association between maternal 25-
hydroxyvitamin D concentration and antenatal depres-
sion. Serum 25-hydroxyvitamin D concentrations were
measured in 4,236 pregnant mothers around their 13 weeks
of gestation and their depression scores were measured at
16 weeks. It has been shown that mothers with higher de-
pression scores had lower levels of 25-hydroxyvitamin D
compared to who had lower depression scores [34]. On the
contrary to the above mentioned studies, Neilson et al., in a
case–control study, found that an increase in 25-
hydroxyvitamin D level can enhance the possibility of post-
natal depression. In this study, they selected mothers who
needed antidepressant drugs after childbirth as the case
group. The mothers who were not on antidepressant drugs
were selected as the control group. They have stated that,
these unexpected results could be due to genetic differences
which lead to a disturbance in conversion of 25-
hydroxyvitamin D into its active form, calcitriol [35].
Vaziri et al. BMC Pregnancy and Childbirth  (2016) 16:239 Page 2 of 12
According to our knowledge, there was no clinical trial
that has evaluated the effectiveness of vitamin D on peri-
natal depression. Hence, we aimed this study to assess the
effectiveness of vitamin D3 supplementation on antenatal
and postnatal depression levels.
Methods
Setting and participants
This randomized clinical trial was done in pregnant
women who were under prenatal care in Hafez hospital
which is a tertiary hospital in Shiraz, Iran, affiliated to
Shiraz University of Medical Sciences. Nulliparous and
multiparous pregnant women were entered into this
study. The inclusion criteria were: being 18 years or older,
healthy women means; any one with no history of mental
illness and internal diseases such as hyper/hypothyroidism,
parathyroid, renal, diabetes and heart diseases, no addiction
to any kind of narcotic drugs, living with a husband, a
singleton live fetus, without any pregnancy complications
such as preeclampsia, gestational diabetes, ruptured mem-
branes and suspicion of preterm birth, no previous cesarean
sections, gestational age of 26–28 weeks based on ultra-
sound results, and the EPDS baseline scores of 0 to 13.
Exclusion Criteria were: the participants with the EPDS
baseline scores of >13, not providing blood sample at
the onset of the study, and less than 8 weeks consumption
of vitamin D3 supplementations (for example due to pre-
term labor or stopping consumption), irregular consump-
tion (for example every two/three days instead of daily
consumption).
In this study, data collection lasted from November
2014 until early October 2015. The present study was
approved by the Ethics Committee of Shiraz University
of Medical Sciences with the ethics code 93–7212. Also,
the present study has been recorded in the Iranian
Registry of Clinical Trials’ website with the code number
IRCT2015020310327N11.
Data collection tools
In this study, we used the Edinburgh Postnatal Depression
scale (EPDS) in order to evaluate depression levels. This
questionnaire is comprised of ten multiple choice ques-
tions, the minimum score is 0 and the maximum is 30.
Advantage of this questionnaire is that it focuses on psy-
chological signs of depression rather than physical signs
[36]. The EPDS was originally utilized in the postpartum
period only. After that, several studies have validated its use
throughout the antenatal period [37–39]. In western stu-
dies, this questionnaire has had high reliability and validity
[40, 41]. It was translated to Persian and was used in the
study by Mazhari and Nakhaee, with a validity and reliabi-
lity of 0.76 and 0.83, respectively [42]. Cut-off points with
values more than 9, 12, 13, and 14 were used in different
studies to determine perinatal depression [37, 43, 44]. In
the present study, we used the cut-off point of > 13 as
greater likelihood of having depression disorder, according
to Mazhari and Nakhaee’s study in Iranian population [42].
Therefore, at baseline we excluded those mothers with the
EPDS scores of >13 and they were referred to a psycho-
logist for further evaluation and management. The cut-off
points of <9 and 9–13 were used as low and moderate risk
for depression.
Serum 25-hydroxyvitamin D was measured with the
Chemiluminescence immunoassay (CLIA) method [45].
After separating the serum from blood sample, the serum
was kept under −20 °C temperature until the laboratory
test was done. The vitamin D measurements were all done
in one laboratory in Shiraz. The lab technicians were blind
to group allocations.
According to the Institute of Medicine (IOM), we consi-
dered vitamin D deficiency as a serum 25-hydroxyvitamin
D of less than 20 ng/ml. We also considered vitamin D in-
sufficiency as a serum 25-hydroxyvitamin D of 21–29 ng/
ml, and the participants who had serum 25-hydroxyvitamin
D of ≥ 30 ng/ml as sufficient [19, 46].
Design and data collection
At first, a research team member who was responsible for
data collection visited the prenatal care clinic of the
hospital daily and based on the inclusion criteria, invited
the mothers to participate in the study. She clarified the
study’s goals and if the mothers were willing to participa-
tion a written informed consent was obtained from them.
The maternal baseline depression levels were evaluated.
The mothers with depression score of 0–13 were entered
in the study. Finally, the candidates were referred to the
lab in order to provide blood samples for determining
serum 25-hydroxyvitamin D concentrations.
Intervention in the supplement consumer (vitamin D)
group: In 2007 and 2010, the Canadian Pediatric Asso-
ciation recommended a daily amount of 2000 IU of vita-
min D for pregnant and breast-feeding women [47, 46].
Therefore, this group received two 1000 unit vitamin D3
pills (Totally 2000 IU) daily from the 26–28 weeks of
gestation until childbirth. The pills were produced by
the Jalinous pharmaceutical company in Iran. The con-
sumptions of pills were assessed in later prenatal care
visits and over the phone. Maternal blood samples were
obtained at 26–28 weeks of gestation (at baseline) and once
more, at childbirth (during first 24 h after birth in postpar-
tum ward). Depression scores were determined four times:
at 26–28 weeks of gestation (baseline), at 38–40 weeks of
gestation, and finally at 4 and 8 weeks after birth. This
group also received routine prenatal care.
Intervention in the control group: the control group
received two placebo pills composed of starch daily from
26 to 28 weeks. Also, other study protocol measures for
this group were similar to the vitamin D group. In Iran,
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iron and folic acid supplements are routinely given to all
pregnant mothers and some mothers based on doctors’
order may consume multivitamins or calcium. In order
not to deprive the participants from antenatal supple-
ments all participating mothers were allowed to use pre-
scribed supplementation outside this study’s protocol. The
multivitamin supplementations contained 200–400 IU of
vitamin D.
Sample size and statistical analysis
We could not find a similar study to use its means for de-
termining the sample size. Therefore, considering the fol-
lowing values: effect size = 0.5, α = 0.05, β = 0.20, to the
power of 80 % and using the formula (16/Δ2, Δ = 0.05),
the sample size was estimated at 64 in each group. Con-
sidering the possible losses, the sample size was set at 74
people in each group finally. Stratified random sampling
was performed in this study. Nulliparous and multiparous
mothers were considered as the strata. In the strata, each
eligible pregnant woman was assigned in the control or
the vitamin D groups using block randomization strategy.
The data were analyzed using the SPSS statistical software
(v. 16). Besides, P-values < 0.05 were considered as statisti-
cally significant. The normality of the data was evaluated
using the Kolmogorov-Smirnov test. The means of normal
distribution data were analyzed using parametric tests
such as Student’s t-test or paired t- test. A non parametric
test (Mann Whitney U test) was used whenever the con-
tinuous measures were not normally distributed. The dis-
tribution of serum 25-hydroxyvitamin D concentration
at baseline and childbirth was not normal in the all parti-
cipants. Therefore, a nonparametric test was used for
25-hydroxyvitamin D data.
We conducted stratified analyses by parity status to
assess whether the trend of effectiveness is different among
the two nulliparous and multiparous subgroups. And
in order to determine changes over time, the repeated
measures analysis was used. Correlations between
continuous.
This was a single-blind study. Data collection related to
depression, at 38–40 weeks of gestation, at 4 and 8 weeks
after birth were done by a trained midwife outside the
research team. She was blind to group allocations.
Results
In this trial study, first 250 pregnant mothers were inter-
viewed. Out of which, 184 qualified mothers were selected
who completed the baseline depression questionnaire.
Amongst them, 15 mothers leaved the study, because their
depression scores were higher than 13. The Remaining
169 participants were assigned to the control or vitamin D
groups with a block randomization design, and they were
referred to the laboratory to provide blood sample. 16/169
women did not refer to the lab. At child birth, blood
sample was collected for 130 mothers. Another significant
factor for sample loss was that a number of the women did
not return to the specified hospital for childbirth. Finally,
136 participants completed the EPDS at 4 and 8 weeks
postpartum. The sampling flow chart was presented in
Fig. 1.
The mean age of the participants was 26.31 ± 4.59. Age
had a minimum and maximum value of 18 and 39,
respectively. Of total participants 92 (60.1 %) mothers
were nulliparous and 61 (39.9 %) were multiparous
women. The two study groups were similar regarding to
age, job, education, parity and sun exposure. However,
they were different regarding to using other supplements
outside the study’s protocol and planned pregnancy
(Table 1).
At baseline, 25-hydroxyvitamin D had a mean value of
12.35 ± 7.17 ng/ with a minimum and maximum value of
4 and 49.30 ng/mL, respectively. This variable had a
median value of 11.20 and mode value of 4. Vitamin D
deficiency (25-hydroxyvitamin D concentration of <20 ng/
mL) was observed in 134 women (87.6 %). Furthermore,
15 women (9.8 %) had insufficiency (25-hydroxyvitamin D
concentration of 20–29 ng/mL). Only, 4 women (2.2 %)
were sufficient (25-hydroxyvitamin D concentration
of ≥ 30 ng/mL).
Age, depression score, amount of sun exposure and
seasons were compared between women with 25-hydro
xyvitamin D concentrations of <20 ng/mL and who had
concentrations of ≥ 20 ng/mL (Table 2).
At childbirth, 25-hydroxyvitamin D had a mean value of
14.64 ± 8.60, with a minimum and maximum value 4 and
51.10 ng/mL, respectively. Ninety-nine women (76.2 %),
25 women (19.2 %), and six women (4.6 %) had 25-hy
droxyvitamin D concentrations of < 20, 20–29 and ≥
30 ng/mL, respectively. The between groups comparisons
of 25-hydroxyvitamin D concentrations were presented in
Table 3.
The mean depression score of 184 participants was 9.20
± 4.44 at baseline. Additionally, a minimum and max-
imum value of 0 and 24, median 9.50, and mode 13 were
observed. Out of which, 79 women (42.9 %) scored <9, 90
women (57.1 %) scored 9–13 and 15 women (8.2 %)
scored > 13. The low risk women for depression (a depres-
sion score of <9) were compared to the high risk women
(a depression score of > 13) concerning age (26.91 ± 4.36
vs. 25.80 ± 4.74) and 25-hydroxyvitamin D concentration
(11.26 ± 6 vs. 13.25 ± 7.96). They did not differ concerning
the two above-mentioned variables, P = 0.09 and p = 0.13,
respectively. The mean depression scores in the nullipa-
rous and multiparous women were 8.58 ± 3.53 and 8.48 ±
4.29, respectively with no significant difference (p = 0.86).
In our study, measures of reliability, including a Cron-
bach’s alpha and a test- retest correlation were 0.86 and
0.92, respectively.
Vaziri et al. BMC Pregnancy and Childbirth  (2016) 16:239 Page 4 of 12
After eliminating some of the mothers who scored > 13,
153 women continued their participation in the study.
Their mean depression score changed to 8.54 ± 3.84. The
median was nine and the mode was 13. Among them, 70
women (45.8 %) scored <9 and 83 women (54.2 %) scored
9–13. At baseline, using Pearson’s correlation coefficient,
no relations were observed between the 25-hydroxyvita
min D concentrations and depression scores (r = 0.13, p =
0.09). There was no significant difference between the two
study groups in relation to the baseline depression scores
(0.74). While, the mean depression scores were signifi-
cantly lower in the vitamin D group than the control one
at 38–40 weeks of gestation (p = 0.01) also, at 4 and 8
weeks after birth (p > 0.001) (Table 3). Depression scores
were divided into three categories, <9, 9–13, and >13, and
using the Fisher’s exact test, the comparisons between the
two groups were conducted. Results showed that in the
vitamin D group the number of participants with depres-
sion scores of <9 were more than the control group at
38–40 weeks of gestation also, at 4 and 8 weeks after birth
(Table 3).
The repeated measures analysis showed that the control
group had gone through significant changes with regards
to depression scores (p < 0.001) (Fig. 2). In pairwise com-
parison, the baseline depression score and the scores at
38–40 weeks were not different significantly (p = 0.142).
Records assessment and interview with 
pregnant mothers (250) 
Not eligible and willing to 
participate (66)
Filled out the EPDS (184)
EPDS score OF>13 
Introduced to medical lab (169)
Not referred to lab  
Checked 25-hydroxy vitamin 
D (153)
Vitamin D group (78) Control group (75)
Preterm labor or not referred
to the hospital
Filled out the EPDS at 38-40 weeks (143)
Checked 25-hydroxyvitamin D at 
childbirth (130)
Not referred to the hospital 
for delivery 
Filled out the EPDS at 4 and 8 weeks postpartum (136)
Preterm birth with 8 
weeks consumption 
Not referred to the hospital for delivery 
but willing to fill out EPDS postpartum
Fig. 1 The flow chart of sampling
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However, the scores at 4 and 8 weeks after birth were
lower than the baseline depression scores ((p = 0.048 and
p = 0.014, respectively).
The vitamin D group also had gone through changes
with regards to their depression scores (p < 0.001) (Fig. 2).
Pairwise comparisons showed that the scores at 38–40
weeks, 4 and 8 weeks postpartum were significantly lower
than the baseline depression scores (p < 0.001).
However, the depression scores at 4 and 8 weeks after
birth were not different significantly (p = 0.217).
The participants were divided in to two subgroups, the
nulliparous and multiparous subgroups and data was
analyzed once more. The results showed that in both
subgroups, the vitamin D group had statistically signi-
ficant higher 25-hydroxyvitamin D concentrations at
childbirth and lower depression score at 4 and 8 weeks
postpartum than the control group (Table 4). While, any
statistically significant differences were not observed
regarding to depression scores at 38–40 weeks of gesta-
tion (Table 4).
We examined the correlation between change in vita-
min D concentrations and change in depression scores
at 38–40 weeks of gestation, 4 and 8 weeks postpartum.
We did not observed any correlation at 38–40 weeks
(r = 0.14, p = 0.29) or at 4 and 8 weeks postpartum (r = 0.1,
p = 0.43) (r = −0.02, p = 0.83) respectively.
Discussion
This clinical trial evaluated the effect of 2000 IU of
vitamin D3 supplement per day during late pregnancy on
perinatal depression. According to our knowledge, this
study was the first trial held on vitamin D and perinatal
depression. Results showed that at baseline, in 72.8 % of
the participants, serum 25-hydroxyvitamin D concentra-
tions were lower than20 ng/mL. They were suffering from
vitamin D deficiency based on new perspective towards
normal serum vitamin D concentration [46]. Although
67.3 % of the blood samples were taken in the winter,
81 % of the participants were exposed to sunlight or had
outdoor activities for at least 15 min per day. Considering
the factors affecting vitamin D production such as cloth-
ing type, skin color and the time of day being exposed to
the sun [48–50], these results are justifiable.
Vitamin D deficiency is a widespread global problem,
which even can observe in the countries which get enough
sunlight [49, 51]. The high prevalence of vitamin D defi-
ciency in Iran was showed in numerous studies. In a study
by Hovsepian et al., in men and women with average age
of 41.4 years in Isfahan, 45 % of men and 52.4 % of women
had vitamin D concentrations lower than 20 ng/mL ([52]).
Saki et al., showed high prevalence of vitamin D deficiency
in southern Iranian children, more than 80 % were defi-
cient [53]. Also, Omani et al. found vitamin D deficiency
in 52.9 % of women aged 20–74 years in Shiraz, Iran [54].
Table 1 Comparison of demographic data in the intervention
and control group
Variables Vitamin D Control p-value
Age (year) Mean ± sd 26.40 ± 4.88 26.22 ± 4.33 0.80
Job N (%) 0.96
Housewife 72 (96) 75 (96.2)
Employed 3 (4) 3 (3.8)
Education N (%) 0.55
High school 26 (34.7) 21 (26.9)
High school diploma 34 (45.3) 38 (48.7)
University 15 (20.0) 19 (24.4)
Parity 0.17
Nullipara 41 (54.7) 51 (65.4)
Multipara 34 (45.3) 27 (34.6)
Using others supplements 0.017
Yes 55 (73.3) 69 (88.5)
No 20 (26.7) 9 (11.5)
Planned pregnancy 0.01
Yes 55 (73.3) 69 (88.5)
No 20 (26.7) 9 (11.5)
Seasonal distribution in onset N (%) 0.32
Autumn 9 (12) 6 (7.7)
Winter 11 (14.7) 7 (9)
Spring 55 (73.3) 65 (83.3)
Sun exposure(minutes) 0.55
< 15 14 (21.9) 12 (16.7)
15–30 28(43.8) 33 (45.8)
30–60 10 (15.6) 17 (23.6)
> 60 12 (18.8) 10 (13.9)
Table 2 Means age and depression score, sun exposure and
seasons in the participants with 25-hydroxyvitamin D
concentrations of <20 and≥ 20 ng/mL




Age (years), mean ± sd 28.45 ± 4.62 25.32 ± 4.39 0.31
Depression score at baseline,
mean ± sd
8.34 ± 3.82 9.37 ± 3.94 0.31
Sun exposure, N (%) <0.001
< 60 m 105 (89.7 %) 8 (44.4 %)
≥ 60 m 12 (10.3 %) 10 (55.6 %)
Season, N (%) 0.05
Spring 24 (75 %) 8 (25 %)
Summer 16 (88.9 %) 2 (11.1 %)
Winter 94 (91.3 %) 9 (8.7 %)
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In a study by Hashempoor et al., in Tehran, 67.1 % of the
men and women had vitamin D concentrations lower than
25 ng/mL [55]. In a study by Kazemi et al., in 67 mothers
with term birth in Zanjan, 86 % in the winter and 46 % in
the summer had vitamin D levels lower than 25 ng/. The
total mean was 19.4 ± 3.9 ng/mL [56]. In the present
study, the mean vitamin D concentrations in vitamin D
group were significantly higher after taking 2000 IU of
vitamin D supplementation per day for at least 8 weeks.
Nonetheless, only 9.7 % in the vitamin D group achieved
serum concentrations higher than 30 ng/mL. In contrast,
in the previous studies 2000 IU vitamin D supplementa-
tion was more sufficient to increase serum 25-hydroxyvi-
tamin D concentrations up to the adequate amount
(≥32 ng/mL) [18, 57, 58]. In those studies, vitamin D
supplementations started at the end of the first trimester
or at the beginning of the second trimester and their
participants had higher initial 25-hydroxyvitamin D con-
centrations compared to the participants in our study.
Ruth et al. in their study used a dosage of 14,000 IU
Table 3 Between groups comparisons of depression scores and 25(OH)D concentrations





P-value Vitamin D group Control group
<9 9–13 >13 <9 9–13 >13 P-value*
Depression score at baseline 8.44 ± 3.89 8.64 ± 3.81 0.747 37 (49.3) 38 (50.7) 0 (0) 33 (42.3) 45 (57.7) 0 (0) 0.383
Depression score at 38–40w gestation 6.17 ± 3.47 7.77 ± 3.92 0.01 49 (72.1) 18 (26.5) 1 (1.5) 37 (50.7) 30 (41.1) 6 (8.2) 0.024
Depression score at post partum (4w) 4.59 ± 3.29 7.36 ± 4.27 <0.001 58 (90.6) 6 (9.4) 0 (0) 43 (59.7) 23 (31.9) 6 (8.3) <0.001
Depression score at postpartum (8w) 4.19 ± 3.76 7.18 ± 3.99 <0.001 57 (89.1) 7 (10.9) 0 (0) 46 (63.9) 22 (30.6) 4 (5.6) 0.001
Categorized 25(OH)D, N(%)
<20 20–29 ≥30 <20 20–29 ≥30 P-value*
25(OH)D at baseline (ng/mL) 12.84 ± 7.91 11.89 ± 6.40 0.63a 65 (86.7) 7 (9.3) 3 (4) 69 (88.5) 8 (10.3) 1 (1.3) 0.61














Fig. 2 Within groups comparison related to depression scores: The results showed, between the two groups, the difference regards to over-time
reduction of depression scores was significant (p < 0.001)
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vitamin D supplement per week, equal to 2000 IU per
day, started at 27–30 weeks of gestation. Of total, 89 %
achieved vitamin D concentration of higher than 20 ng/
mL and 56 % achieved vitamin D concentration of higher
than 32 ng/mL [57]. In Tehran, Taheri et al. gave 2000 IU
of vitamin D per day to non-pregnant women in form of
oral drops for 105 days. Initial mean 25-hydroxyvitamin D
level was 9.35 ± 6.33 ng/mL in the control group and was
10.05 ± 7.38 ng/mL in the intervention group. After inter-
vention, the two groups were different significantly.
Almost half of the intervention group achieved concentra-
tions of 30 ng/mL [59]. Maternal 25-hydroxyvitamin D
transfers to the fetus by the placenta. Therefore, it is justi-
fiable that in our study, vitamin D group had lower
25-hydroxyvitamin D concentration compared to those
were in the study by Taheri et al.
Considering cut-off point of ≥9, data analysis showed
that a lot of participants (more than 50 %) were suscep-
tible to prenatal depression at 26–28 weeks. When using
cut-off point of >13, susceptibility to prenatal depression
decreases to 8.2 %. In previous studies, the prevalence of
antenatal depression had been studied, using various tools
and cut-off points. In a cohort study by Evans et al. 11.8 %
at 18 weeks and 13.5 % at 32 weeks were depressed with
the threshold score of 13 or higher [60]. In a study in a
private center in Brazil, the prevalence of antenatal
depression was 19.6 % with the Beck tool [61]. In a study
by Shackle et al. in Oslo, prevalence of depression at
28 weeks was 13 % in all of samples. Depression was
reported in 8.6 % of European mothers, in 19.5 % of
Middle Eastern mothers, and in 17.5 % of South Asian
mothers. The threshold of ≥10 was used based on the
EPDS [62]. However, the EPDS has been widely used in
screening, not providing a diagnosis, for perinatal depres-
sion, it has been reported that its score is highly correlated
with physician diagnostic opinion. Several studies have
been shown that, with cutoff score of 12–13, this scale
develops into more indicative in identifying real depres-
sion in women [36, 37, 42]. The participants who had
depression scores of >13 were exited from this clinical trial
and referred to psychiatrist for further assessment and
treatment, because, the nature of our study was preventa-
tive than management.
In our study, antenatal depression score had no asso-
ciation with the baseline 25-hydroxyvitamin D concentra-
tion. While in a study by Cassidy- Bushrow et al., in
African-American women, an inverse relationship was
observed between maternal 25-hydroxyvitamin D concen-
tration at the early stages of pregnancy and antenatal
depression. There was an inverse relationship between the
vitamin D logarithm and depression scores, as by adding
one unit to the vitamin D concentration logarithm, equal
to 2.72 ng/mL, a 46 % reduction in the depression scores
occurred [63]. In another study in US, in 498 pregnant
mothers with the mean gestational age of 15 weeks, gene-
rally there was an inverse relationship between 25-hydro
xyvitamin D concentration and depression level. With
1 ng/mL reduction in 25-hydroxyvitamin D concentration,
the anxiety and depression levels increased 0.043 and
0.040, respectively [64]. It is worth mentioning that their
tools for determining depression were different than ours.
In our study, nearly 70 % of the mothers had vitamin D
deficiency. It was a possible reason that we did not
observe any relationship between antenatal depression
score and 25-hydroxyvitamin D concentration. Also in
our study, selection of participants at the beginning was
through convenience method. Surprisingly, the change
in vitamin D concentration (baseline to childbirth) was
not correlated with changes in depression scores from
baseline to 38–40 weeks of gestation or to 4 and 8 weeks
postpartum.
The present trial showed that consuming 2000 IU vita-
min D3 per day in late pregnancy was effective in decreas-
ing depression scores in perinatal period. The vitamin D
and control groups were similar regarding to general char-
acteristics except for two variables: unplanned pregnancy
and using other supplements out of the study’s protocol.
Unplanned pregnancy was more frequent in the vitamin D
group than the control group. Previous studies reported
that unplanned pregnancy is a risk factor for perinatal
depression. Nonetheless, in our study, the vitamin D group
had significantly lower depression scores after intervention.
Table 4 25(OH)D concentrations and depression scores in nulliparous and multiparous subgroups
Variables Mean (sd) Nulliparous Multiparous
Vitamin D group Control group N p-value Vitamin D group Control group N p-value*
25(OH)D at baseline (ng/mL) 13.13(6.91) 13.25 (6.55) 41/51 0.93 12.49 (9.08) 9.31 (5.34) 34/27 0.15
25(OH)D at delivery (ng/mL) 18.40 (11.38) 12.49 (6.29) 33/43 0.01 16.58 (8.54) 11.36 (5.47) 28/25 0.02
Depression score at baseline 8.41(3.52) 8.73 (3.57) 41/51 0.67 8.47 (4.35) 8.48 (4.30) 34/27 0.99
Depression score at 38-40w gestation 6.47(3.43) 7.98 (3.74) 38/46 0.06 5.80 (3.62) 7.44 (4.28) 30/27 0.12
Depression score at postpartum (4w) 4.59(3.24) 7.27 (4.04) 34/45 0.002 4.60 (3.40) 7.52 (4.70) 30/27 0.01
Depression score at postpartum (8w) 4.18(3.79) 7.24 (3.79) 34/45 0.001 4.20 (3.79) 7.07 (4.37) 30/27 0.01
*Mann–Whitney U test
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The effectiveness of calcium supplementation on preven-
tion of perinatal depression has been shown in a previous
study [65]. The control group consumed extra supplements
such as calcium more frequently, nonetheless this group
had significantly higher depression scores compared to vita-
min D group.
Previous clinical trials, in which vitamin D supplementa-
tions were consumed during pregnancy [18, 58], have not
evaluated the antenatal and postnatal depression disor-
ders. However in a cross-sectional study in Japan, higher
dietary vitamin D intake was independently associated
with a lower prevalence of depressive symptoms during
pregnancy [66].
On the other hand, the effect of vitamin D on depres-
sion in non-pregnant people are not entirely clear. Some
clinical trials in non-pregnant people showed that vitamin
D was effective in decreasing depression level. In a study
by Mozafari- Khosravi et al., 300,000 and 150,000 IU
vitamin D were administered by injection to the two
groups who suffered depression and the third group did
not receive vitamin D. High doses of vitamin D were
effective in decreasing depression levels after 3 months
[30]. In another study, 20,000 and 40,000 IU vitamin D
per week were given to the obese and overweight people
for one year. Comparing to the control group, depression
level decreased in both intervention groups [67]. In
contrast, in another study 40,000 IU vitamin D per week
was used for 6 months, but vitamin D was not effective in
decreasing depression level compared to the control
group [68]. Dean et al. found that 5000 IU vitamin D per
day for 6 weeks had no effect on men and women’s cogni-
tive and emotional function [69].
Vitamin D can affect brain function in several ways. The
existence of receptors for the active form of vitamin D (1,
25(OH)2D) in the brain induces a direct effect. The essen-
tial enzymes for vitamin D hydroxylation are found in the
brain that can produce calcitriol. Its indirect effects are
attributed to vitamin D’s effects on improvement of
muscle activities. As a result of this improvement, physical
activity increases and this have positive effects on health.
An increase in vitamin D can cause parathyroid hormones
to decrease. An increase in this hormone can lead to brain
dysfunctions [70, 71]. On the other hand, cytokines are
messengers produced by immune cells which affect all
tissues, including brain. Nowadays, we know that brain
cells such as microglia and astrocytes, can secrete cyto-
kines. Besides, activated lymphocytes can cross the blood–
brain barrier and secrete cytokines in the brain [72].
Vitamin D may act as an anti-inflammatory agent in the
brain by keeping harmful pro-inflammatory cytokines
in check. Vitamin D deficiency has been linked to pro-
inflammatory disease. It is also possible that as a result of
vascular changes in pregnancy the maternal cerebral
environment is more vulnerable to inflammation perhaps,
explaining in part the link between vitamin D and depres-
sion in pregnancy. In light of the inflammatory nature of
depression and the strong role of vitamin D as an anti-
inflammatory and immunomodulator, inflammation may
mediate the relationship between vitamin D deficiency
and depression during pregnancy [73, 74].
Previous studies have suggested that perinatal depres-
sion is more frequent and serious in primiparous women
than multiparous women [75, 76]. It was interesting to
investigate trend of vitamin D effectiveness in the two
primiparous and multiparous subgroups. The findings
were similar to the overall population except one thing.
As, in the two subgroups, the depression scores were not
significantly lower in vitamin D group compared to con-
trol group at 38–40 weeks. Staying on vitamin D con-
sumption until childbirth resulted in higher serum 25-hy
droxyvitamin D concentration that induced the effect on
postnatal depression exceeding than prenatal depression.
A difference in nature of antenatal depression compared
to postnatal depression can reflect another possible reason
for achieving this result.
Depression scores decreased in the both our groups
over time which indicates that depression could be more
critical during pregnancy than postpartum period.
The pleasant feeling of motherhood can probably play a
role in decreasing depression specially in primiparous
mothers [77]. During pregnancy, women are worried
about risks to their own and the fetus health. Fear of labor
pain is another concern of the modern-day mothers [78].
Therefore, a decreased perinatal depression level is justifi-
able. On the other hand, the difference between the two
groups was meaningful concerning over-time reduction of
depression. Meaning that over time, depression scores
decreased much more in the vitamin D group in compa-
rison to control group and this shows the possible effects
of the vitamin D3 supplementation. Another finding
of this study was that vitamin D3 supplementation was
effective in decreasing depression level in both nulliparous
and multiparous subgroups.
Limitations
Vitamin D consumption by mothers was merely con-
trolled through reminders during prenatal care visits or
over the phone. Therefore, the participants’ honesty was
one of this research limits. The participants were selected
from one prenatal clinic. This group of participants may
not be representative of the target population. Since
mothers with depression level of >13 were excluded from
this study, the results can not extend to mothers with high
levels of depression. Also, since more than 95 % of the
mothers had lower than 30 ng/mL serum 25-hydroxyvita-
min D concentration, it is not clear if the same results
would be observed in mothers with higher levels of 25-
hydroxyvitamin D. Therefore, we suggest further clinical
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trials, using 2000 IU vitamin D on a larger population,
mothers with high levels of depression, and high serum
25-hydroxyvitamin D concentrations. The last weakness
of this study was that it had the statistical authority to
identify differences in depressive symptoms, but not in the
diagnoses of major depressive disorder.
Conclusion
In the present study, it was observed that 2000 IU vitamin
D3 per day for at least 8 weeks during late pregnancy, can
be effective in decreasing perinatal depression levels
(at 38–40 weeks of gestation also, at 4 and 8 weeks after
birth). Most pregnant mothers tolerated the 2000 IU well
without any adverse effects and just a few of them tempo-
rarily complained about nausea.
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